<DOC>
	<DOCNO>NCT02794857</DOCNO>
	<brief_summary>This study evaluate NP001 patient amyotrophic lateral sclerosis ( ALS ) evidence systemic inflammation . Half participant receive NP001 half receive placebo .</brief_summary>
	<brief_title>Safety Efficacy Study NP001 Patients With Amyotrophic Lateral Sclerosis ( ALS ) Systemic Inflammation</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study NP001 subject ALS evidence elevate systemic inflammation . Subjects allocate ( 1:1 ) NP001 placebo . Drug placebo give intravenously .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Key Diagnosis clinically possible , clinically probable ( without laboratory support ) , clinically definite ALS ( use revise El Escorial Criteria ) Forced vital capacity great equal 65 % predict age height Onset ALSrelated weakness le 3 year prior first dose study drug Plasma high sensitivity Creactive protein ( hsCRP ) concentration great equal 0.113 mg/dL prescreening/screening Stable dose ( great 30 day ) riluzole undergo treatment agent For female : Not childbearing potential agree use adequate birth control study Key Life expectancy le 6 month Tracheotomy use ventilatory assistance , include Bilevel Positive Airway Pressure ( BiPAP ) Continuous Positive Airway Pressure ( CPAP ) Active pulmonary disease Gastrostomy Stem cell therapy Immune modulator therapy participation study agent within 12 week prescreening/screening Unstable medical condition ALS</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ALS</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Neuromuscular Diseases</keyword>
	<keyword>Inflammation</keyword>
	<keyword>C-Reactive Protein</keyword>
</DOC>